Targeted Inactivation of Fh1 Causes Proliferative Renal Cyst Development and Activation of the Hypoxia Pathway

Cancer Cell

Volumn 11, Issue 4, 2007, Pages 311-319

  Pollard, Patrick J ^a   Spencer Dene, Bradley ^a,b   Shukla, Deepa ^b   Howarth, Kimberley ^a   Nye, Emma ^a,b   El Bahrawy, Mona ^b   Deheragoda, Maesha ^a   Joannou, Maria ^a,b   McDonald, Stuart ^a   Martin, Alison ^a   Igarashi, Peter ^c   Varsani Brown, Sunita ^a   Rosewell, Ian ^a   Poulsom, Richard ^a   Maxwell, Patrick ^b   Stamp, Gordon W ^a,b   Tomlinson, Ian P M ^a,d  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

CELLCYCLE

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; EMBRYO; EMBRYONIC STEM CELL; FH1 GENE; GENE; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC PREDISPOSITION; GLUT1 GENE; HYPOXIA; KIDNEY CARCINOMA; KIDNEY CYST; LEIOMYOMATOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; VEGF GENE;

MURINAE;

EID: 34047167041     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2007.02.005     Document Type: Article

References (46)

1. Alam N.A., Rowan A.J., Wortham N.C., Pollard P.J., Mitchell M., Tyrer J.P., Barclay E., Calonje E., Manek S., Adams S.J., et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum. Mol. Genet. 12 (2003) 1241-1252
2. Alam N.A., Olpin S., and Leigh I.M. Fumarate hydratase mutations and predisposition to cutaneous leiomyomas, uterine leiomyomas and renal cancer. Br. J. Dermatol. 153 (2005) 11-17
3. Baysal B.E., Willett-Brozick J.E., Lawrence E.C., Drovdlic C.M., Savul S.A., McLeod D.R., Yee H.A., Brackmann D.E., Slattery III W.H., Myers E.N., et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J. Med. Genet. 39 (2002) 178-183
4. Binienda Z.K., Sadovova N.V., Rountree R.L., Scallet A.C., and Ali S.F. Effect of L-carnitine pretreatment on 3-nitropropionic acid-induced inhibition of rat brain succinate dehydrogenase activity. Ann. N Y Acad. Sci. 939 (2001) 359-365
5. Boado R.J., and Pardridge W.M. Glucose deprivation and hypoxia increase the expression of the GLUT1 glucose transporter via a specific mRNA cis-acting regulatory element. J. Neurochem. 80 (2002) 552-554
6. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394 (1998) 485-490
7. Gimenez-Roqueplo A.P., Favier J., Rustin P., Mourad J.J., Plouin P.F., Corvol P., Rotig A., and Jeunemaitre X. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am. J. Hum. Genet. 69 (2001) 1186-1197
8. Gimenez-Roqueplo A.P., Favier J., Rustin P., Rieubland C., Kerlan V., Plouin P.F., Rotig A., and Jeunemaitre X. Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J. Clin. Endocrinol. Metab. 87 (2002) 4771-4774
9. Goldenring J.R., Poulsom R., Ray G.S., Wright N., Meise K.S., and Coffey Jr. R.J. Expression of trefoil peptides in the gastric mucosa of transgenic mice overexpressing transforming growth factor-alpha. Growth Factors 13 (1996) 111-119
10. Greaves L.C., Preston S.L., Tadrous P.J., Taylor R.W., Barron M.J., Oukrif D., Leedham S.J., Deheragoda M., Sasieni P., Novelli M.R., et al. Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission. Proc. Natl. Acad. Sci. USA 103 (2006) 714-719
11. Huminiecki L., Chan H.Y., Lui S., Poulsom R., Stamp G., Harris A.L., and Bicknell R. Vascular endothelial growth factor transgenic mice exhibit reduced male fertility and placental rejection. Mol. Hum. Reprod. 7 (2001) 255-264
12. Iliopoulos O., and Kaelin Jr. W.G. The molecular basis of von Hippel-Lindau disease. Mol. Med. 3 (1997) 289-293
13. Isaacs J.S., Jung Y.J., Mole D.R., Lee S., Torres-Cabala C., Chung Y.L., Merino M., Trepel J., Zbar B., Toro J., et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. Cancer Cell 8 (2005) 143-153
14. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J.M., Lane W.S., and Kaelin Jr. W.G. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 292 (2001) 464-468
15. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., Kriegsheim A., Hebestreit H.F., Mukherji M., Schofield C.J., et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292 (2001) 468-472
16. Kiuru M., and Launonen V. Hereditary leiomyomatosis and renal cell cancer (HLRCC). Curr. Mol. Med. 4 (2004) 869-875
17. Kiuru M., Launonen V., Hietala M., Aittomaki K., Vierimaa O., Salovaara R., Arola J., Pukkala E., Sistonen P., Herva R., and Aaltonen L.A. Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology. Am. J. Pathol. 159 (2001) 825-829
18. Kivela A.J., Parkkila S., Saarnio J., Karttunen T.J., Kivela J., Parkkila A.K., Bartosova M., Mucha V., Novak M., Waheed A., et al. Expression of von Hippel-Lindau tumor suppressor and tumor-associated carbonic anhydrases IX and XII in normal and neoplastic colorectal mucosa. World J. Gastroenterol. 11 (2005) 2616-2625
19. Lehtonen H.J., Kiuru M., Ylisaukko-Oja S.K., Salovaara R., Herva R., Koivisto P.A., Vierimaa O., Aittomaki K., Pukkala E., Launonen V., and Aaltonen L.A. Increased risk of cancer in patients with fumarate hydratase germline mutation. J. Med. Genet. 43 (2005) 523-526
20. Levy A.P., Levy N.S., and Goldberg M.A. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. J. Biol. Chem. 271 (1996) 25492-25497
21. Lisztwan J., Imbert G., Wirbelauer C., Gstaiger M., and Krek W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 13 (1999) 1822-1833
22. Maher E.R., and Kaelin Jr. W.G. von Hippel-Lindau disease. Medicine (Baltimore) 76 (1997) 381-391
23. Mandriota S.J., Turner K.J., Davies D.R., Murray P.G., Morgan N.V., Sowter H.M., Wykoff C.C., Maher E.R., Harris A.L., Ratcliffe P.J., and Maxwell P.H. HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1 (2002) 459-468
24. Masson N., and Ratcliffe P.J. HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O(2) levels. J. Cell Sci. 116 (2003) 3041-3049
25. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., and Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
26. Nagy A., Gertsenstein M., and Bintersten K.R. Manipulating the Mouse Embryo: A Laboratory Manual. Third Edition (2003), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
27. Pollard P., Wortham N., Barclay E., Alam A., Elia G., Manek S., Poulsom R., and Tomlinson I. Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome. J. Pathol. 205 (2005) 41-49
28. Pollard P.J., Briere J.J., Alam N.A., Barwell J., Barclay E., Wortham N.C., Hunt T., Mitchell M., Olpin S., Moat S.J., et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1{alpha} in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 14 (2005) 2231-2239
29. Poulsom R., Longcroft J.M., Jeffery R.E., Rogers L.A., and Steel J.H. A robust method for isotopic riboprobe in situ hybridisation to localise mRNAs in routine pathology specimens. Eur. J. Histochem. 42 (1998) 121-132
30. Pugh C.W., and Ratcliffe P.J. Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat. Med. 9 (2003) 677-684
31. Rankin E.B., Higgins D.F., Walisser J.A., Johnson R.S., Bradfield C.A., and Haase V.H. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol. Cell. Biol. 25 (2005) 3163-3172
32. Rankin E.B., Tomaszewski J.E., and Haase V.H. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res. 66 (2006) 2576-2583
33. Raval R.R., Lau K.W., Tran M.G., Sowter H.M., Mandriota S.J., Li J.L., Pugh C.W., Maxwell P.H., Harris A.L., and Ratcliffe P.J. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 25 (2005) 5675-5686
34. Schofield C.J., and Ratcliffe P.J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 5 (2004) 343-354
35. Selak M.A., Armour S.M., MacKenzie E.D., Boulahbel H., Watson D.G., Mansfield K.D., Pan Y., Simon M.C., Thompson C.B., and Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7 (2005) 77-85
36. Shao X., Johnson J.E., Richardson J.A., Hiesberger T., and Igarashi P. A minimal Ksp-cadherin promoter linked to a green fluorescent protein reporter gene exhibits tissue-specific expression in the developing kidney and genitourinary tract. J. Am. Soc. Nephrol. 13 (2002) 1824-1836
37. Shao X., Somlo S., and Igarashi P. Epithelial-specific Cre/lox recombination in the developing kidney and genitourinary tract. J. Am. Soc. Nephrol. 13 (2002) 1837-1846
38. Talks K.L., Turley H., Gatter K.C., Maxwell P.H., Pugh C.W., Ratcliffe P.J., and Harris A.L. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157 (2000) 411-421
39. Taylor R.W., Barron M.J., Borthwick G.M., Gospel A., Chinnery P.F., Samuels D.C., Taylor G.A., Plusa S.M., Needham S.J., Greaves L.C., et al. Mitochondrial DNA mutations in human colonic crypt stem cells. J. Clin. Invest. 112 (2003) 1351-1360
40. Tomlinson I.P., Alam N.A., Rowan A.J., Barclay E., Jaeger E.E., Kelsell D., Leigh I., Gorman P., Lamlum H., Rahman S., et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30 (2002) 406-410
41. Toro J.R., Nickerson M.L., Wei M.H., Warren M.B., Glenn G.M., Turner M.L., Stewart L., Duray P., Tourre O., Sharma N., et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am. J. Hum. Genet. 73 (2003) 95-106
42. Wang G.L., Jiang B.H., Rue E.A., and Semenza G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 92 (1995) 5510-5514
43. Wykoff C.C., Beasley N.J., Watson P.H., Turner K.J., Pastorek J., Sibtain A., Wilson G.D., Turley H., Talks K.L., Maxwell P.H., et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 60 (2000) 7075-7083
44. Xia G., Kageyama Y., Hayashi T., Hyochi N., Kawakami S., and Kihara K. Positive expression of HIF-2alpha/EPAS1 in invasive bladder cancer. Urology 59 (2002) 774-778
45. Yoshimura H., Dhar D.K., Kohno H., Kubota H., Fujii T., Ueda S., Kinugasa S., Tachibana M., and Nagasue N. Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin. Cancer Res. 10 (2004) 8554-8560
46. Zeevalk G.D., Derr-Yellin E., and Nicklas W.J. Relative vulnerability of dopamine and GABA neurons in mesencephalic culture to inhibition of succinate dehydrogenase by malonate and 3-nitropropionic acid and protection by NMDA receptor blockade. J. Pharmacol. Exp. Ther. 275 (1995) 1124-1130